New Equilibrium Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- New Equilibrium Biosciences's estimated annual revenue is currently $852.5k per year.
- New Equilibrium Biosciences's estimated revenue per employee is $77,500
- New Equilibrium Biosciences's total funding is $10.3M.
Employee Data
- New Equilibrium Biosciences has 11 Employees.
- New Equilibrium Biosciences grew their employee count by -50% last year.
New Equilibrium Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Operations Manager | Reveal Email/Phone |
2 | Principal Scientist, Computational Chemistry | Reveal Email/Phone |
New Equilibrium Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is New Equilibrium Biosciences?
New Equilibrium Bioscience's mission is to aid the development of new medicines for life-threatening diseases with a focus on extending the health span of patients. We leverage our computational-experimental platform to discover lead drug candidates that regulate intrinsically disordered proteins implicated in cancers and neurodegenerative disorders.
keywords:N/A
$10.3M
Total Funding
11
Number of Employees
$852.5k
Revenue (est)
-50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
New Equilibrium Biosciences News
... (FACS) Aria II SORP or FACS Aria Fusion cell sorter (BD Biosciences). ... After the stepwise minimizations, the MD equilibrium phase,...
The MIM mechanism is efficient in generating new species in an exponential ... the PSMC pattern has not yet reached the low equilibrium.
New Equilibrium Biosciences, a Cambridge, Mass.-based company that advances a rational drug design against intrinsically disordered proteins (IDPs), closed a $10m in seed funding. RA Capital Management made the investment. New Equilibrium previously closed $350k in grants from the National Scie ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.8M | 11 | -31% | $19.6M |
#2 | $1M | 11 | N/A | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $0.9M | 11 | N/A | N/A |
#5 | $0.9M | 11 | -8% | $11.2M |